Health & Biotech
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Investor Guides
Investor Guide: Health & Biotech FY2023
Experts
ScoPo’s Powerplays: ‘Big haircuts’ for ASX health stocks – Morgans reviews quarterly results
Health & Biotech
ASX Health Stocks: Emyria takes its MDMA-inspired drugs to the next level
News
ASX Quarterlies: Companies shine amidst market volatility
Health & Biotech
Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand
Health & Biotech
Creso Pharma’s acquisition target lands deal with leading US online health marketplace
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Health & Biotech
Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence
Health & Biotech
Could Aussie cannabinoid companies help solve a global opioid crisis?
Health & Biotech
Creso Pharma shares surge ~12% after inking tattoo sector deal
Health & Biotech
Weed Week: Will the US Senate pass the MORE act, and Swiss cannabis wellness spas are a thing
Health & Biotech
ASX Health Stocks: UK FSA welcomes Cann’s CBD capsules onto its approved list
Stockhead TV
V-Con: Medicinal cannabis – which global firms will take the $US35 billion cake?
Health & Biotech
Creso Pharma’s Halucenex gets green light for Phase 2 clinical trial of psilocybin for PTSD
Health & Biotech
Stock Insiders: Legendary Canadian cannabis entrepreneur Bruce Linton on the sector’s future and why he’s backing Creso Pharma
News
Weed Week: The Super Bowl bans weed ads even though Snoop is the halftime act
Health & Biotech